Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 1:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 468 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cardiovascular Inflammation Clear all
Completed Early Phase 1 Interventional Accepts healthy volunteers

PPG Project 3 - PET/MRI of the Brain-hematopoiesis-atherosclerosis Axis in PTSD Patients

NCT03279393
View directory record Official record
Conditions
PTSD, Trauma, Healthy
Interventions
fluorodeoxyglucose (FDG)-PET/MRI
Drug
Lead sponsor
Zahi Fayad
Other
Eligibility
30 Years to 65 Years
Enrollment
190 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Jul 22, 2026, 1:38 AM EDT
Completed Phase 4 Interventional Results available

Effect of Raltegravir on Endothelial Function in HIV-Infected Patients

NCT00843713
View directory record Official record
Conditions
HIV Infection, Inflammation, Cardiovascular Disease, HIV Infections
Interventions
raltegravir, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Jul 22, 2026, 1:38 AM EDT
Completed Phase 3 Interventional Results available

Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults

NCT02344290
View directory record Official record
Conditions
HIV, Cardiovascular Diseases
Interventions
Pitavastatin, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
40 Years to 75 Years
Enrollment
7,769 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
91
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 59 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Jul 22, 2026, 1:38 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Effect of Aspirin on Hemostatic and Vascular Function After Live Fire Fighting

NCT01276691
View directory record Official record
Conditions
Cardiovascular Risk Factor, C.Medical Procedure; Vascular, Functional or Late, Electrolyte and Fluid Balance Conditions
Interventions
81 mg enteric coated aspirin
Drug
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
40 Years to 60 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Champaign, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Jul 22, 2026, 1:38 AM EDT
Completed Not applicable Interventional

Trial of Aerobic Exercise Training in Stroke Survivors

NCT00891514
View directory record Official record
Conditions
Stroke, Insulin Resistance, Sedentary Lifestyle
Interventions
Aerobic Exercise, Stretching
Behavioral
Lead sponsor
Baltimore VA Medical Center
Federal
Eligibility
40 Years to 75 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Jul 22, 2026, 1:38 AM EDT
Completed Early Phase 1 Interventional

Using Ferumoxytol-Enhanced MRI to Measure Inflammation in Patients With Brain Tumors or Other Conditions of the CNS

NCT02452216
View directory record Official record
Conditions
Brain Injury, Central Nervous System Degenerative Disorder, Central Nervous System Infectious Disorder, Central Nervous System Vascular Malformation, Hemorrhagic Cerebrovascular Accident, Ischemic Cerebrovascular Accident, Primary Brain Neoplasm, Brain Cancer, Brain Tumors
Interventions
Ferumoxytol, Tissue Analysis, Magnetic Resonance Imaging
Drug · Other · Procedure
Lead sponsor
Michael Iv
Other
Eligibility
2 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Jul 22, 2026, 1:38 AM EDT
Completed Not applicable Interventional Results available

Study of the Arachidonate 5-Lipoxygenase Enzyme in Affecting the Risk for Coronary Heart Disease

NCT00379808
View directory record Official record
Conditions
Coronary Heart Disease
Interventions
montelukast, Placebo
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 22, 2012 · Synced Jul 22, 2026, 1:38 AM EDT
Not yet recruiting Not applicable Interventional

Bypass Clear Priming VSD Cardiopulmonary Bypass Circuit Reduce Bypass Associated Inflammation?

NCT07393243
View directory record Official record
Conditions
Ventricular Septal Defect
Interventions
Clear priming of the bypass pump
Procedure
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
1 Month to 18 Months
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Jul 22, 2026, 1:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Feasibility of an Endotoxemia Model

NCT01329965
View directory record Official record
Conditions
Cardiovascular Disease, Inflammation
Interventions
LPS (reference endotoxin, E. coli O113:H10:K:neg, manufactured under GMP)
Drug
Lead sponsor
Penn State University
Other
Eligibility
20 Years to 35 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 20, 2023 · Synced Jul 22, 2026, 1:38 AM EDT
Completed Phase 2 Interventional

Management of Cardiovascular Disease in Kidney Disease (MaCK) Study

NCT03636152
View directory record Official record
Conditions
Chronic Kidney Disease, Cardiovascular Disease, Inflammation, Atherosclerosis, Aortic Stiffness
Interventions
MRI carotid, APWV, Hydroxychloroquine, Matching Placebo
Procedure · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 9, 2025 · Synced Jul 22, 2026, 1:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Diet and Systemic Inflammation

NCT01424306
View directory record Official record
Conditions
Low-grade Chronic Inflammation, Intestinal Permeability, Type 2 Diabetes Mellitus, Cardiovascular Disease, Obesity
Interventions
Fructose-sweetened beverages, Glucose-sweetened beverages, High-fructose corn syrup-sweetened beverages
Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 13, 2017 · Synced Jul 22, 2026, 1:38 AM EDT
Completed No phase listed Observational

Myocardial Inflammation in Rheumatoid Arthritis: A Descriptive Study

NCT03776682
View directory record Official record
Conditions
Myocardial Inflammation, Rheumatoid Arthritis, Coronary Artery Disease, Myocardial Strain
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 9, 2023 · Synced Jul 22, 2026, 1:38 AM EDT
Withdrawn Phase 3 Interventional

Vitamin C and Atrial Fibrillation After Cardiac Surgery

NCT01580683
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Ascorbic Acid, Identical Placebo
Drug · Other
Lead sponsor
Regional Hospital of Scranton
Other
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Scranton, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Jul 22, 2026, 1:38 AM EDT
Completed Not applicable Interventional Results available

Post-stroke Fatigue, Inflammation, tDCS

NCT05330988
View directory record Official record
Conditions
Stroke, Fatigue, Chronic Stroke, Stroke Sequelae
Interventions
anodal transcranial direct current stimulation (a-tDCS), sham stimulation
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
35 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Jul 22, 2026, 1:38 AM EDT
Completed Not applicable Interventional Results available

Reducing CVD Risk in Caregivers: A Brief Behavioral Activation Intervention

NCT01802554
View directory record Official record
Conditions
Depressive Symptoms, Inflammation
Interventions
Pleasant Events Program (PEP), Information Support (IS)
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
55 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 12, 2016 · Synced Jul 22, 2026, 1:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Carotid Doppler Ultrasound for the Measurement of Intravascular Volume Status

NCT02907931
View directory record Official record
Conditions
Hypotension, Sepsis
Interventions
Point of Care Ultrasound
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 60 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 12, 2020 · Synced Jul 22, 2026, 1:38 AM EDT
Completed Phase 2 Interventional Results available

Use of Rosuvastatin in HIV-Infected Subjects to Modulate Cardiovascular Risks

NCT01218802
View directory record Official record
Conditions
HIV Infections, Heart Disease
Interventions
Rosuvastatin 10 mg. daily for 96 weeks, Placebo
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 7, 2016 · Synced Jul 22, 2026, 1:38 AM EDT
Terminated Phase 2 Interventional

Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).

NCT04433546
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Coronavirus, Hypoxic Respiratory Failure, Hypoxemic Respiratory Failure, Respiratory Complication, Respiratory Insufficiency, Cardiac Dysfunction, Pneumonia, Pulmonary Edema, Pulmonary Inflammation, Respiratory Failure, Cytokine Storm, COVID 19, SARS-CoV-2, Cardiac Event, Cardiac Complication, Cardiac Failure, Cardiac Infarct
Interventions
Pemziviptadil (PB1046), Low Dose (10 mg) Control
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
4
States / cities
Jacksonville, Florida • Sarasota, Florida • Kansas City, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Jul 22, 2026, 1:38 AM EDT
Completed Not applicable Interventional Results available

Depression Therapy to Improve Cardiovascular Risk in HIV

NCT02309372
View directory record Official record
Conditions
Depression, HIV
Interventions
Beating the Blues
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Jul 22, 2026, 1:38 AM EDT
Completed Not applicable Interventional Results available

Efficacy of Nitric Oxide Administration in Attenuating Ischemia/Reperfusion Injury During Neonatal Cardiopulmonary Bypass

NCT02151877
View directory record Official record
Conditions
Ischemia/Reperfusion Injury After Neonatal Cardiac Surgery, Inflammatory Reaction After Neonatal Cardiac Surgery
Interventions
Inhaled Nitric Oxide, placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
1 Day to 30 Days
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Oak Lawn, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Jul 22, 2026, 1:38 AM EDT
Completed Phase 4 Interventional Results available

The RAS, Fibrinolysis and Cardiopulmonary Bypass

NCT00607672
View directory record Official record
Conditions
Coronary Artery Disease, Angiotensin Converting Enzyme, Angiotensin Receptor Blockers, Cardiopulmonary Bypass, Fibrinolysis, Inflammation
Interventions
Placebo, Ramipril, Candesartan
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 80 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 9, 2012 · Synced Jul 22, 2026, 1:38 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Thrombosis and Inflammation in Vessels Initiative (TIVI)

NCT06552767
View directory record Official record
Conditions
Cardiovascular Diseases, Vascular Diseases
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
5 Years to 100 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2034
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 22, 2026, 1:38 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Dose Response Effects of Marine Omega-3 Fatty Acids on Inflammation

NCT01078909
View directory record Official record
Conditions
Cardiovascular Disease, Inflammation
Interventions
Eicosapentaenoic Acid and Docosahexaenoic Acid (EPA + DHA)
Biological
Lead sponsor
Penn State University
Other
Eligibility
20 Years to 45 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 20, 2023 · Synced Jul 22, 2026, 1:38 AM EDT
Completed Not applicable Interventional

Cleaner Air for Lower Cardiometabolic Risk

NCT05994937
View directory record Official record
Conditions
PreDiabetes
Interventions
PAC with HEPA filter intact, PAC with HEPA filter removed
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 85 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Jul 22, 2026, 1:38 AM EDT